[MIK HOT SPOT_KHIDI] Immunomax presents self-memory T cell-based anti-cancer immune cell treatment drug and virus vaccine high-efficiency production animal cell line improvement technology
Immunomax, which participated in MIK Hot Spot (Made in Korea Online Exhibition) KHIDI introduced its self-memory T cell-based anti-cancer immune cell treatment drug and virus vaccine high-efficiency production animal cell line improvement technology.
Company Overview
Hello, this is Park Se-ho Ho, CEO of
Immunomax. Immunomax is a company that develops biopharmaceuticals based on
immune system regulation. I have been studying virus vaccines and anti-cancer
drugs for more than 20 years at Korea University, and I would like to
contribute to overcoming diseases by developing accumulated technologies as
biopharmaceuticals.
Background for Development and Product Competitiveness 1 - Virus vaccine high-efficiency production animal cell line technology
To produce the virus vaccine highly
efficiently, Immunomax selected specific genes related to productivity through
big data analysis. Through genetic manipulation, it has established a platform
technology that can produce 2-3 times more virus vaccines or antibodies than
existing animal cell lines. This technology is an important technology that can
quickly respond to the outbreak of a pandemic virus such as COVID-19, and is an
excellent platform technology that enables rapid and mass production of
treatment drugs. Cell lines with technology have the same effect as
conventional vaccines and are highly productive at the same time. We have eight
domestic and foreign patents on this technology to secure and protect our
technology.
Background for Development and Product Competitiveness 2 - Anti-cancer immuno-memory T cell treatment drug
Immunmax's second flagship product is the
anti-cancer immune cell therapy. Conventional immune T cell treatment drugs
have little or no effect, and if they are good, they cause side effects such as
cytokine storms, and have safety problems. As a way to solve this problem,
using the memory T cells is known to be effective, but it had not been
successfully commercialized. We Immunomax have secured memory T cell
enhancement technology through basic research for a long time, so we are
developing treatment drugs to maximize treatment effects and minimize side
effects. The anti-cancer effects have been confirmed in animal models.
Reliability
Immunomax is located in Korea University
Industry-University Building, and has successfully accumulated approximately 8
billion won in investment since its establishment in October 2015. It is a
R&D company with 13 experts composed of Master's degree in relevant
studies. Park Se-ho is a professor at Korea University who is an expert in
immunology with 18 patents registered and presented and 77 papers published.
Expansion: Market Entry Strategy (Marketing)
We intend to actively promote technology
and products at home and abroad through clinical research papers and
conferences/exhibitions, and make new sales channels with technology transfer
and copyright agreements. In the case of the domestic market, we have a
strategy to seek market entry through cooperation with companies with
nationwide sales networks.
Performance and Investment Issues
The foundation for the commercialization of
cell treatment drugs has been built with 2019 Startup Leap Project, and we aim
to begin the clinical trial on the immune cell treatment drugs on 2021 and be
listed on KOSDAQ in 2023. We would like to grow as a major company of K-Bio by
treating incurable diseases such as cancer and autoimmune diseases and
developing vaccines and treatment drugs for infectious diseases by controlling
immunity. Contact Number: 02-6946-8700 / Email: information.imx@gmail.com
The products and services of the major
companies of KHIDI Health Industry Startup Innovation Center in the MIK Hot
Spot (Made in Korea Online Exhibition) will also be displayed in BIO KOREA
2020. Asia's biggest bio convention BIO KOREA 2020 co-organized by KHIDI and
Chungbuk Province and sponsored by MOHW will be open online due to the COVID-29
pandemic on May 18-23. Virtual exhibition halls, conference, and business
forums will be operated, and the companies will be promoting their
competitiveness. Also, with video meetings, businesses between overseas
speakers, buyers, and domestic and foreign participating companies will be
made. To date, more than 160 companies have applied for the virtual exhibition
booth at BIO KOREA 2020. Companies wishing to participate can apply through the
web page or email by Apr. 30.
The global news network AVING News has
begun holding the MIK Hot Spot (Made in Korea Online Exhibition) to help small
and medium-sized companies enter the market and attract investment 365 days a
year. AVING News has been running online exhibitions since 2005 and had 975
online exhibitions so far. Its YouTube online exhibition has placed itself as
Korea's largest online exhibition hall that opens with 19,000 videos (booths)
with more than 800,000 visits per month which means more than 10 million visits
per year.
The MIK Hot Spot online exhibition is
scheduled to be held regularly according to the field, target market, and
participating institutions, and it will be presented as a new type of online
business by transforming the know-hows and values of the participating
companies according to the trend. Companies that want to participate can apply
and apply through the marketing support projects from supporting institutions
in the local governments. Refer to the institutions for more information.
RSS